PHILADELPHIA, PA — Context Therapeutics Inc. (NASDAQ: CNTX) said it has granted non-qualified stock option awards covering a total of 120,000 shares of common stock to two newly hired employees as inducement compensation tied to their acceptance of employment.
The awards were issued outside the company’s 2021 Long-Term Performance Incentive Plan and were made in accordance with Nasdaq Listing Rule 5635(c)(4), which permits equity grants to new employees as a material inducement to hire.
The options were granted on the employees’ respective start dates, January 1, 2026, and January 12, 2026. Exercise prices were set at the closing price of Context’s common stock on the applicable grant dates, or the most recent closing price if no trades occurred, resulting in exercise prices of $1.47 and $1.49 per share.
Each stock option carries a 10-year term and vests over four years. One-quarter of the underlying shares will vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments thereafter. Vesting is contingent on the employee’s continued service with the company through each applicable vesting date.
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for the treatment of solid tumors. Its pipeline includes multiple investigational programs targeting oncology indications, with research centered on advancing next-generation immunotherapies.
The company said the inducement awards are intended to support recruitment efforts as it continues to build out its scientific and operational capabilities.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.